According to Blueprint Medicines
's latest financial reports the company has a price-to-book ratio of 52.0.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 42.9 | 742.97% |
2022-12-31 | 5.09 | -21.55% |
2021-12-31 | 6.49 | 52.7% |
2020-12-31 | 4.25 | -49.98% |
2019-12-31 | 8.50 | 50.03% |
2018-12-31 | 5.67 | 7.87% |
2017-12-31 | 5.25 | 20.63% |
2016-12-31 | 4.35 | -12.06% |
2015-12-31 | 4.95 | |
2014-12-31 | N/A |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Pacific Biosciences
PACB | 0.7262 | -98.60% | ๐บ๐ธ USA |
OPKO Health
OPK | 0.6522 | -98.75% | ๐บ๐ธ USA |
Isoray
ISR | 1.95 | -96.26% | ๐บ๐ธ USA |